[ad_1] Coherus BioSciences’ partnership to offer deeply discounted biosimilar Humira can go only so far in reducing overall prices. [ad_2] Source link
Tag: AMGN
WSJ News Exclusive | New Drugs for Cancer, Rare Disease Can Now Cost More Than $20,000 a Month
[ad_1] WSJ News Exclusive Health Trend follows rising pressure on companies to rein in repeat or annual price hikes for older drugs [ad_2] Source link
The Dow Industrials Are Sitting Out the Stock Market’s Wild Ride
[ad_1] The Dow Jones Industrial Average last year was a relative bright spot in a battered stock market. Now, speculation is back, and the blue chips are falling behind. [ad_2]…
Drugmakers Raise Prices on Nearly 1,000 Medicines but Show Restraint
[ad_1] Health List prices climb by 5.6% on average as new federal law aims to lower drug costs [ad_2] Source link
A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them.
[ad_1] Pharmaceutical companies could try to blunt the limits on future price increases. [ad_2] Source link
As the U.S. Gets Older, Some ETFs Bet on Aging in Place
[ad_1] A number of thematic funds are focused on companies that help seniors who want to stay in their homes as long as possible. [ad_2] Source link
Investors’ Best Friend in 2022: The Dogs of the Dow
[ad_1] The 10 stocks with the highest dividend yields of the Dow components at the beginning of last year rose 2.2%. [ad_2] Source link
Drugmakers Spent Freely in 2022 to Protect Revenue
[ad_1] Pfizer, Amgen and Bristol-Myers Squibb bought makers of proven drugs ahead of potential rising competition from generics. [ad_2] Source link
Amgen Hunts for New Revenue in $28 Billion Deal
[ad_1] Health The purchase of Horizon brings in rare-disease drugs with billions of dollars in sales that could offset revenue drops from patent expiries [ad_2] Source link